ASLAN Pharmaceuticals (ASLN) Stock Price, News & Analysis

Company Overview

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.

Key Stats

• Today's Range: $0.60 to $0.60
• 50-Day Range: $0.60 to $0.60
• 52-Week Range: $0.48 to $25.44
• Volume: N/A
• Average Volume: 122,322 shs
• Market Capitalization: $1.23 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ASLN Stock Analysis - Frequently Asked Questions

How have ASLN shares performed this year?

ASLAN Pharmaceuticals' stock was trading at $0.60 at the start of the year. Since then, ASLN shares have increased by 0.0% and is now trading at $0.60.

How were ASLAN Pharmaceuticals' earnings last quarter?

ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) announced its earnings results on Friday, August, 11th. The company reported ($0.88) EPS for the quarter, beating analysts' consensus estimates of ($6.40) by $5.52. The company earned $12 million during the quarter.

When did ASLAN Pharmaceuticals' stock split?

ASLAN Pharmaceuticals's stock reverse split on Wednesday, July 3rd 2024.The 1-8 reverse split was announced on Wednesday, July 3rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

When did ASLAN Pharmaceuticals IPO?

ASLAN Pharmaceuticals (ASLN) raised $60 million in an initial public offering on Friday, May 4th 2018. The company issued 7,500,000 shares at a price of $8.05 per share. Leerink Partners and Piper Jaffray served as the underwriters for the IPO and BTIG, H.C. Wainwright and CLSA were co-managers.

How do I buy shares of ASLAN Pharmaceuticals?

Shares of ASLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ASLAN Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ASLAN Pharmaceuticals investors own include Tesla (TSLA), Sorrento Therapeutics (SRNE), Bionano Genomics (BNGO), Meta Platforms (META), Zoom Communications (ZM), Fulgent Genetics (FLGT) and Inovio Pharmaceuticals (INO).

Company Calendar

• Last Earnings: 8/11/2023
• Today: 7/03/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ASLN
• CIK: 1722926
• Web: www.aslanpharma.com
• Phone: 65-6817-9598
• Fax: 65-6225-2419
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($21.92)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$44.22 million
• Net Margins: N/A
• Pretax Margin: -290.83%
• Return on Equity: -8,454.87%
• Return on Assets: -121.60%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.05
• Quick Ratio: 1.05

Sales & Book Value

• Annual Sales: $12 million
• Price / Sales: 0.10
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($6.50) per share
• Price / Book: -0.09

Miscellaneous

• Outstanding Shares: 2,044,000
• Free Float: 1,948,000
• Market Cap: $1.23 million
• Optionable: Optionable
• Beta: 1.40